Lightstone Ventures
VC Fund
Menlo Park, United States
Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing inbreakthrough life science companies during a time of unique opportunity in space.
- Total investments:
- 88
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $375M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Lightstone Ventures invests in
Stages Lightstone Ventures invests in
Countries Lightstone Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 15 contacts → | |||
Round size
- Series A
- $20M–$95M
- Series B
- $18M–$100M
- Series C
- $20M–$105M
Investment Focus
Industry
- Biotechnology 31 (35%)
- Health Care 28 (32%)
- Therapeutics 19 (22%)
- Medical 18 (20%)
- Medical Device 13 (15%)
Stage
- Series A 21 (24%)
- Series B 19 (22%)
- Series C 12 (14%)
- Series D 4 (5%)
- Funding Round 4 (5%)
Country
- United States 32 (36%)
- Ireland 3 (3%)
- India 2 (2%)
- Singapore 2 (2%)
- United Kingdom 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Caroline Gaynor
Principal
|
Principal | Total investments: 5 | Find email | |
Christina Isacson
Partner
|
Partner | Total investments: 2 | Find email | |
Christopher M. Owens
Founder, President & CEO
|
Founder, President & CEO | Total investments: 0 | Find email | |
Christopher M. Owens
Founder, President & CEO
|
Founder, President & CEO | Total investments: 0 | Find email | |
Hank Plain
Partner
|
Partner | Total investments: 20 | Find email | |
| See all 15 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $20M / Series C / May 12, 2026 | ||
| Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. | $47.5M / Series A / Dec 10, 2025 | ||
| Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M / Series A / Sep 30, 2025 | ||
| Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. | $32M / Series A / Sep 09, 2025 | ||
| ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $80M / Series B / Aug 25, 2025 | ||
| Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enableimproved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. | $61M / Series B / Aug 13, 2025 | ||
| Apreo Health is developer of medical apparatus designed for diagnosing or treating respiratory, pulmonary, and lung conditions. | $130M / Series B / Aug 07, 2025 | ||
| Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M / Series D / Jun 05, 2025 | ||
| Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $150M / Series C / Apr 02, 2025 | ||
| Trotana Therapeutics is a biotech company that focuses on the discovery and development of medicines targeting RNA-binding proteins. | $52.5M / Series A / Feb 01, 2025 | ||
| See all 88 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lightstone Ventures invest in?
Lightstone Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 88 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Lightstone Ventures's check size?
Lightstone Ventures typically joins rounds of $20M–$95M at Series A, $18M–$100M at Series B and $20M–$105M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lightstone Ventures participates in.
How do I contact Lightstone Ventures?
Public channels for Lightstone Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lightstone Ventures?
The team at Lightstone Ventures includes Caroline Gaynor (Principal), Christina Isacson (Partner) and Christopher M. Owens (Founder, President & CEO), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
